NCT00002337已完成1 期
A Phase I Safety and Tolerability Study of Four Doses of OPC-8212 (Vesnarinone) in Advanced HIV Disease
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 56
- 试验地点
- 2
研究概览
简要总结
To evaluate the safety and tolerability of four doses of oral vesnarinone in patients with advanced HIV disease.
详细描述
Fourteen patients per dose level receive vesnarinone at 1 of 4 doses for 12 weeks. At least seven patients at a given dose level must have completed 4 weeks of treatment before dose is escalated in subsequent patients.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
A Long-Term, Follow-On Safety Study of Four Doses of OPC-8212 (Vesnarinone) in HIV-Infected PersonsHIV InfectionsNCT00002130Otsuka America Pharmaceutical
已完成
1 期
A Phase I Study of Three Doses of OPC-8212 (Vesnarinone) in HIV-Infected Persons With CD4+ Cell Number > 300 Cells/mm3HIV InfectionsNCT00002129Otsuka America Pharmaceutical36
已完成
1 期
Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic SyndromeMyelodysplastic SyndromeNCT01048619Traws Pharma, Inc.36
已完成
1 期
Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid TumorsLocally Advanced Solid TumorsMetastatic Solid TumorsPancreatic AdenocarcinomaNCT02045602Theriva Biologics SL42
已完成
1 期
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacology of ONO-4474 in Healthy VolunteersOsteoarthritisNCT02454387Ono Pharmaceutical Co. Ltd141